BioCentury
ARTICLE | Finance

Ebb & Flow

June 13, 2005 7:00 AM UTC

Although six of MPM Capital's eight original general partners will be leaving to form their own firm - Clarus Ventures - the breakup is not a vote against MPM's mega-fund model. Indeed, MPM's Nicholas Galakatos, who will be a managing director at Clarus, told Ebb & Flow that the new firm will employ many of the strategies of MPM's $900 million MPM BioVentures III.

"The fund will continue the strategy that most of us were involved in designing in BioVentures III," he said. "The centerpiece will be a focus on products as the key value driver. We'll want to lead investments and do so with significant capital," investing $20-$30 million per company. ...